New imaging agent could predict CAR-T success in lymphoma patients

NCT ID NCT06522932

Recruiting now Knowledge-focused Sponsor: Michael Randall Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study is testing a new radioactive tracer called 64Cu-GRIP B, which is used in PET scans to detect immune cell activity. The goal is to see if this scan can predict which patients with relapsed non-Hodgkin lymphoma will have a lasting response to CAR-T cell therapy. About 32 adults will receive the tracer before and after CAR-T treatment, and some will also have optional tumor biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 64Cu-GRIP B (a radioactive tracer for PET scans)
What this could lead to: If successful, this imaging method could help doctors quickly identify which lymphoma patients are likely to benefit from CAR-T therapy, avoiding ineffective treatments.
What could go wrong: This is a very early, small study (32 people) focused on imaging, not treatment. The tracer may not reliably predict responses, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.